<DOC>
	<DOCNO>NCT00087620</DOCNO>
	<brief_summary>To evaluate compare time progression combination capecitabine ( 825 mg/m2 twice daily ) docetaxel ( 75mg/m2 i.v . ) capecitabine ( 1000 mg/m2 twice daily ) progressive disease follow sequentially docetaxel ( 75 mg/m2 i.v . D1 Q3W ) .</brief_summary>
	<brief_title>A Study Capecitabine In Combination With Docetaxel v Capecitabine Followed Docetaxel As First-Line Treatment For Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Have provide write informed consent prior study specific screening procedure , understand patient right withdraw study time , without prejudice Be female least 18 year age . Note : must 19 year age patient resident state Alabama Be ambulatory ( outpatient ) Karnofsky performance status 70 % Have confirm breast cancer locally advance and/or metastasis Have least one site define tumor Have meet one study definition primary nonprimary resistance anthracyclinecontaining therapy Pregnant/lactating woman Women childbearing potential either positive pregnancy test Women childbearing potential unless use reliable appropriate contraceptive method ( Postmenopausal woman must period least 12 month consider nonchildbearing potential ) Prior treatment chemotherapy advanced/metastatic set HER 2/neu positive status without prior treatment trastuzumab Prior treatment IV bolus 5FU , continuous 5FU infusion , capecitabine oral fluoropyrimidines Prior treatment taxane le 12 month pass time therapy completion relapse Mitomycin C nitrosoureas within 6 week precede treatment start Organ allografts require immunosuppressive therapy Radiotherapy skeleton within 4 week study treatment start insufficient recovery effect prior radiotherapy Hormonal therapy within 10 day precede study treatment start Major surgery within 4 week prior study treatment start , lack complete recovery effect major surgery Blood transfusions/growth factor aid hematologic recovery within 2 week prior study treatment start Participation investigational drug study within 4 week precede treatment start Prior unanticipated severe reaction fluoropyrimidine therapy Known hypersensitivity 5fluorouracil , taxanes component capecitabine Requirement concurrent use antiviral agent sorivudine chemically related analogue Evidence CNS metastases History another malignancy within last five year except cure basal cell carcinoma skin carcinoma Clinically significant ( i.e . active ) cardiac disease Abnormal laboratory value Severe renal impairment Serious uncontrolled intercurrent infection , serious uncontrolled concomitant disease Lack physical integrity upper GI tract Life expectancy le 3 month Unwilling/unable comply protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>